Study on the molecular diagnosis of metastasis and recurrence and molecular targeted therapy for intractable hepato-pancreatic cancer
Study on the molecular diagnosis of metastasis and recurrence and molecular targeted therapy for intractable hepato-pancreatic cancer
批准号:
20249061
负责人:
ARII Shigeki
金额:
$30.87万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2011
中文摘要
根据对肝细胞癌临床标本的DNA微阵列分析,极光激酶B被确定为唯一独立的致死性复发预测因子。临床前试验表明,极光激酶B的特异性抑制剂是治疗侵袭性肝癌的有前景的药物,其独特的基因表达特征与肝细胞癌的形态进展密切相关。特别是,干细胞标记物EpCAM可能在融合型多结节型肝癌的侵袭性中起关键作用。在核微环境中转运系统的变化中,我们利用肝细胞癌组织的微阵列分析了Importin家族。研究表明:(1)肿瘤特异性高甲基化介导的miR-124和miR-203沉默是原发性肝癌中较为常见的分子事件;(Ii)miR-124和miR-203通过下调其潜在靶点的表达抑制细胞生长,导致细胞周期分别停滞于G1、S检查点和细胞凋亡。我们发现非癌肝组织中细胞色素P1A2表达下调是早期肝癌复发的预测因素。采用前瞻性多中心队列的验证性研究证实了非癌性CYP1A2的重要性。GSEA显示,CYP1A2与肝组织中的氧化应激途径密切相关。我们使用蛋白酶体活性水平的荧光标记系统来鉴定具有肿瘤干细胞(CSCs)特征的胰腺癌细胞。我们筛选并鉴定了一种对胰腺干细胞有特殊毒性的化合物。
英文摘要
According to the DNA microarray analysis using clinical samples of hepatocellular carcinoma(HCC), aurora kinase B was identified as the only independent predictor of the lethal recurrence. Preclinical tests revealed the specific inhibitor of aurora kinase B was the promising agent to treat the aggressive HCC.The distinct signature of gene expression closely related to the morphological progression in HCC. Especially, a stem cell marker EpCAM might play a critical role in the aggressiveness of confluent multinodular type of HCC.Among the alterations of transport system in the nuclear microenvironment, we focused on the importin family using microarray analysis of HCC tissues. Importin alpha1 was identified as a molecule activated functionally in HCC cells, and its significance was also validated clinicopathologically.The study showed that(i) tumor-specific hypermethylation-mediated silencing of miR-124 and miR-203 was a relatively frequent molecular event in primary HCCs and(ii) miR-124 and miR-203 exert cell growth-inhibitory effect with the downregulation of their potential targets, resulting in cell cycle arrest at the G1 S checkpoint and apoptosis, respectively.We identified the downregulation of CYP1A2 in non-cancerous liver tissue as a predictive factor for recurrence of early-stage HCC. The significance of non-cancerous CYP1A2 was confirmed by validation study using the prospective multi-center cohort. GSEA revealed that close association of CYP1A2 was implicated with the oxidative stress pathways in liver tissue.We used a fluorescence marker system for level of proteasome activity to identify pancreatic cancer cells with features of cancer stem cells(CSCs). We screened and identified a compound that is specifically toxic to the pancreatic CSCs.
期刊论文(115)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
難治性癌の肝細胞性解析に基づく分子標的治療の開発と応用
基于肝细胞分析的难治性癌症分子靶向治疗的开发与应用
DOI:
--
发表时间:
2011
期刊:
影响因子:
--
作者:
[山本れいこ, ら, 田中真二,村形綾乃,村松俊輔,アディクリスナラマ,茂櫛薫,伴大輔,入江工,野口典男,工藤篤,中村典明,中山恒,田中博,田賀哲也,有井滋樹]
通讯作者:
田中真二,村形綾乃,村松俊輔,アディクリスナラマ,茂櫛薫,伴大輔,入江工,野口典男,工藤篤,中村典明,中山恒,田中博,田賀哲也,有井滋樹
ミニシンポジウム・肝胆膵癌の分子標的治療肝癌臨床検体のオミックス解析を基盤とする分子標的の同定と前臨床試験への展開
小型研讨会:肝胆胰癌分子靶向治疗基于肝癌临床标本组学分析的分子靶点识别及临床前研究进展
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[Chiho Takahashi, Hiroyuki Yoshida, Akihiko Komine, Kazuhisa Nakao, Takashi Tsuji, Yasuhiro Tomooka., 田中真二,藍原有弘,伴大輔,野口典男,入江工,工藤篤,中村典明,有井滋樹]
通讯作者:
田中真二,藍原有弘,伴大輔,野口典男,入江工,工藤篤,中村典明,有井滋樹
ミニシンポジウム・肝胆膵癌の分子標的治療 肝癌臨床検体のオミックス解析を基盤とする分子標的の同定と前臨床試験への展開
小型研讨会:肝胆胰癌分子靶向治疗基于临床肝癌样本组学分析的分子靶点识别及临床前研究进展
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[田中真二, 藍原有弘, 伴大輔, 野口典男, 入江工, 工藤篤, 中村典明, 有井滋樹]
通讯作者:
有井滋樹
パネルディスカッション・外科臨床に基づいた難治性消化器癌の分子標的治療の開発
圆桌讨论/基于外科临床实践开展难治性胃肠癌分子靶向治疗
DOI:
--
发表时间:
2010
期刊:
影响因子:
--
作者:
[大島正充, 辻孝, 川口章, 田中真二,藍原有弘,野口典男,入江工,工藤篤,中村典明,有井滋樹]
通讯作者:
田中真二,藍原有弘,野口典男,入江工,工藤篤,中村典明,有井滋樹
Liver Cancer Study Group of Japan Surgical resection vs percutaneous ablation for hepatocellular carcinoma : A preliminary report of the Japanese nationwide survey
日本肝癌研究小组肝细胞癌的手术切除与经皮消融:日本全国调查的初步报告
DOI:
--
发表时间:
2008
期刊:
J Hepatology
影响因子:
--
作者:
[Hasegawa K, Makuuchi M, TakayamaT, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, Ikai I]
通讯作者:
Ikai I
共 81 条
Multidisciplinary research for molecular mechanism of cancer progression and development of diagnostic and therapeutic tool
-
批准号:18209043
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$32.03万
-
财政年份:2006
-
负责人:ARII Shigeki
-
依托单位:
Development of molecular- targeting therapy and prediction of mode of recurrence by analysis of molecular mechanism of invasion and metastasis of hepatocellular carcinoma
-
批准号:16390375
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.15万
-
财政年份:2004
-
负责人:ARII Shigeki
-
依托单位:
Order-made medicine for cancer in the viewpoint of angiogenesis
-
批准号:14370379
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.34万
-
财政年份:2002
-
负责人:ARII Shigeki
-
依托单位:
Study on the improvement of liver injury by controlling sinusoidal cells and spleen
-
批准号:12470257
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.02万
-
财政年份:2000
-
负责人:ARII Shigeki
-
依托单位:
Development of novel gene therapies in the field of liver surgery
-
批准号:09557104
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.0万
-
财政年份:1997
-
负责人:ARII Shigeki
-
依托单位:
Pathophysiology of the liver and development of a novel therapeutics based on morphological and functional study on hepatic sinusoidal
-
批准号:08457322
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.93万
-
财政年份:1996
-
负责人:ARII Shigeki
-
依托单位:
Implication of hepatic sinusoidal cells in pathophysiology of the liver diseases and development of novel therapeutic strategies
-
批准号:06454383
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.61万
-
财政年份:1994
-
负责人:ARII Shigeki
-
依托单位:
海外基金